BioWorld

Sep. 5, 2007

View Archived Issues

J. Craig Venter Institute Publishes J. Craig Venter Genome Sequence

Clinical Data's Vilazodone Positive In Phase III Study

GNI Gains New Listing In Japan Raises $7.7M For Drug Discovery

Anacor Seeks $57.5M In IPO For Topical Boron-Based Pipeline

Other News To Note

Clinic Roundup

NeurogesX Reports Positive Phase III Study Of NGX-4010

NeurogesX Inc. reported the pain patch NGX-4010 met primary and secondary endpoints in a third Phase III trial, and the second in patients with postherpetic neuralgia. (BioWorld Today) Read More

Acambis Smallpox Vaccine Finally Wins U.S. Approval

Today's news in brief

BioWorld

BioWorld briefs for Feb. 2, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...

First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

BioWorld Science

Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...

Illustration of brain with neuron receptor

5-HT2R allosteric ligands attenuate cocaine use and seeking behavior

BioWorld Science

Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...